Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jun 26;5(6):e59.
doi: 10.1038/ctg.2014.7.

Qualitative development of a patient-reported outcome symptom measure in diarrhea-predominant irritable bowel syndrome

Affiliations

Qualitative development of a patient-reported outcome symptom measure in diarrhea-predominant irritable bowel syndrome

P Marquis et al. Clin Transl Gastroenterol. .

Abstract

Objectives: Despite a documented clinical need, no patient reported outcome (PRO) symptom measure meeting current regulatory requirements for clinically relevant end points is available for the evaluation of treatment benefit in diarrhea-predominant IBS (IBS-D).

Methods: Patients (N=113) with IBS-D participated in five study phases: (1) eight concept elicitation focus groups (N=34), from which a 17-item IBS-D Daily Symptom Diary and four-item IBS-D Symptom Event Log (Diary and Event Log) were developed; (2) one-on-one cognitive interviews (N=11) to assess the instrument's comprehensiveness, understandability, appropriateness, and readability; (3) four data triangulation focus groups (N=32) to confirm the concepts elicited; (4) two hybrid (concept elicitation and cognitive interview) focus groups (N=16); and (5) two iterative sets of one-on-one cognitive interviews (N=20) to further clarify the symptoms of IBS-D and debrief a revised seven-item Diary and four-item Event Log.

Results: Of thirty-six concepts initially identified, 22 were excluded because they were not saturated, not clinically relevant, not critical symptoms of IBS-D, considered upper GI symptoms, or too broad or vaguely defined. The remaining concepts were diarrhea, immediate need (urgency), bloating/pressure, frequency of bowel movements, cramps, abdominal/stomach pain, gas, completely emptied bowels/incomplete evacuation, accidents, bubbling in intestines (bowel sounds), rectal burning, stool consistency, rectal spasm, and pain while wiping. The final instrument included a daily diary with separate items for abdominal and stomach pain and an event log with four items completed after each bowel movement as follows: (1) a record of the bowel movement/event and an assessment of (2) severity of immediacy of need/bowel urgency, (3) incomplete evacuation, and (4) stool consistency (evaluated using the newly developed Astellas Stool Form Scale). Based on rounds of interviews and clinical input, items considered secondary or nonspecific to IBS-D (rectal burning, bubbling in intestines, spasms, and pain while wiping) were excluded.

Conclusions: The IBS-D Symptom Diary and Event Log represent a rigorously developed PRO instrument for the measurement of the IBS-D symptom experience from the perspective of the patient. Its content validity has been supported, and future work should evaluate the instrument's psychometric properties.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Instrument evolution by development phase.
Figure 2
Figure 2
Final four-item IBS-D Symptom Event Log with stool descriptors and images of the Astellas Stool Form Scale (a) and seven-item IBS-D Daily Symptom Diary (b).
Figure 2
Figure 2
Final four-item IBS-D Symptom Event Log with stool descriptors and images of the Astellas Stool Form Scale (a) and seven-item IBS-D Daily Symptom Diary (b).
Figure 3
Figure 3
Conceptual framework resulting from qualitative research.

References

    1. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130:1480–1491. - PubMed
    1. Grundmann O, Yoon SL. Irritable bowel syndrome: epidemiology, diagnosis and treatment: an update for health-care practitioners. J Gastroenterol Hepatol. 2010;25:691–699. - PubMed
    1. Gilkin RJ., Jr The spectrum of irritable bowel syndrome: a clinical review. Clin Ther. 2005;27:1696–1709. - PubMed
    1. US Department of Health and Human Services, Food and Drug Adminstration, Center for Drug Evaluation and Research Guidance for Industry: Irritable Bowel Syndrome—Clinical Evaluation of Products for Treatment, Silver Spring, MD,2012
    1. Committee for Medicinal Products for Human Use Concept paper on the revision of the CHMP points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome (CPMP/EWP/785/97)European Medicines Agency, May2012

LinkOut - more resources